Galapagos (GLPG) announced that the FDA has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Deutsche Bank downgrades Galapagos to Sell amid ‘too much uncertainty’
- Galapagos downgraded to Sell from Hold at Deutsche Bank
- Galapagos Hold Rating: Navigating Management Changes and Strategic Uncertainties
- Galapagos NV Reports 2025 Half-Year Results and Strategic Updates
- Galapagos NV Reports Strong H1 2025 Results Amid Strategic Transformation